Featured Opinions
Defining brands and why they are critical to success in healthcare.
Pharma Missing Out on Pre-Treatment Services Opportunity
by Jeff Elton
By offering pre-treatment services, pharma can become the "go to" resource from the start of the patient journey.
by Marc Yates
What are the opportunities and challenges for pharma companies wishing to gain a foothold in this oil-rich kingdom?
Key Considerations for Successful Data Collaborations
Why this trend has surfaced and key considerations for pharmaceutical companies actively exploring their own collaborations.
Patients, Promises & Politics: Who Can You Trust?
To whom do we entrust our health decisions?
by Jill Donahue
When we focus on patients first, business follows. The time has come to serve differently.
In Defense of Innovation: Value-Based Reimbursement & Contracting
by Jeff Elton
Value-based reimbursement and contracting will become mainstream as reimbursement authorities move away from ‘cost’ as the focus towards ‘value.’
Examining the Physician’s View of Medication Adherence
Most physicians are likely to overestimate their own patients’ adherence rates, according to a Healthprize survey.
Our new column focuses on building great healthcare brands: strong, tangible brands with a clear purpose, anchored to customer needs and the relevant market.
Take Charge of Your Digital Marketing Once and For All
It took a while, but the pharma industry is finally becoming aware that digital approaches may hold the key to transforming the way they market drugs and interact with their customers.
The Dilemma for MNCs in China: New Technology vs. Old?
Healthcare spending in China has more than doubled from $156bn in 2006 to $357bn in 2011 and is estimated to reach $1tn by 2020 – about 6 per cent of the country’s GDP.
Turkey: Identifying the Growth Drivers
by Marc Yates
What are the drivers of this expansion of private healthcare in Turkey? And what the opportunities and implications for global pharma?
New columnists Tina Boggiano & Doug Haggstrom explore pharma's role in digital health.
Building a High-Performance Organization
One of the eternal questions for leaders is: what makes a High-Performance Organization? Lots of companies claim to be High-Performance Organizations. The real thing is rare, however, and instantly recognizable.
Market Segmentation in the New Healthcare Landscape
In order to remain competitive, pharmaceutical companies must shift their focus to smaller, more targeted patient populations.
Pat Andrews has been involved in some major industry contributions over two decades and now faces new opportunities with a pioneering R&D company, Boston Biomedical.
Breakthrough science, not safe science
If we want innovation we must be bolder at what we do, Bernard Munos argues in the first of his new monthly columns for eyeforpharma.
What if We Could Be Heroes, not Villains..
by David Laws
Dale Partridge, founder of Sevenly, is living proof that new, socially conscious business models are not only imminent but also surprisingly profitable. What if valuing people over profit was actually more profitable for pharma?
Leading a Renaissance in Alzheimer's
FORUM Pharmaceuticals CEO and President Deborah Dunsire made the move from the oncology sphere into dementia-related illnesses. She tells Danielle Barron why she likes to stay at the cutting edge of research, while always keeping her eye on the prize – better outcomes for patients.
Chronic Disease Management in China
Patient Self-Management Can Overcome an Important Healthcare Gap
Impactful Presentations in 4 Easy Steps
by Anonymous (not verified)
Working at a business intelligence company, I spend a lot of time at conferences and obviously I come across some stellar presentations. The good news is that's its all entirely coachable.
Selling to IDNs: Strategies for Success
Changes in healthcare delivery are rapidly undermining traditional pharmaceutical commercial models. Customers are fewer and larger as hospitals consolidate into integrated delivery networks in the face of rising cost pressures, stiffer financial penalties and the imperatives of healthcare reform.
Decency as a Driver of Excellence
Dr Nicola Davies speaks to Mette Aagaard Hertz, Corporate Vice President at Novo Nordisk and Head of Human Resources in Research and Development, about pharma’s responsibility to maintain high standards in the fight against global health problems.
Patient centricity – from hubris to humility
In January I was ‘treated’ by 10 HCPs in 7 days and more than 100 patients in 24 hours. The medics managed my physical state; the patients guided my psychological well-being, helping me reach decisions and an understanding more readily by sharing their information and experiences.
Rethinking Pharma Part 3: Why Pharma are Giving Away the Golden Goose
In the 3rd installment of Rethinking pharma, Dr Andree Bates talks about value creation and why she thinks pharma is giving its value away.